The mTOR signaling pathway is upregulated in 15–50% of patients with HCC [22, 23], and mutations of TSC-1/TSC-2 and LKB1, which encode regulators of mTOR signaling, are observed in 5% of HCC patients [24]. This evidence concerns the gene MTOR and hepatocellular carcinoma.